Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Solid Tumors
NCT07185893Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of romiplostim in Thrombocytopenia (2 arms). Primary endpoint: Proportion of patients achieving response within 14 days. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT07185893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185893.